within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BG06_Exemestane;

model Exemestane
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.42,
    Cl = 6.861111111111111e-06,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.048,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006516666666666667,
    Tlag = 15.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Exemestane</td></tr><tr><td>ATC code:</td><td>L02BG06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>48</td><td>L</td></tr>
    <tr><td>clearance:</td><td>24.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Exemestane is a steroidal aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer, primarily in postmenopausal women. It reduces the production of estrogen and is approved for use as adjuvant or advanced treatment for breast cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as observed in healthy postmenopausal females after oral administration of a single 25 mg exemestane dose.</p><h4>References</h4><ol><li><p>Valle, M, et al., &amp; Verotta, D (2005). A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. <i>British journal of clinical pharmacology</i> 59(3) 355–364. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2005.02335.x\">10.1111/j.1365-2125.2005.02335.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15752382/\">https://pubmed.ncbi.nlm.nih.gov/15752382</a></p></li><li><p>Zhang, Q, et al., &amp; Jiang, Z (2018). Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. <i>Chinese journal of cancer research = Chung-kuo yen cheng yen chiu</i> 30(6) 605–612. DOI:<a href=\"https://doi.org/10.21147/j.issn.1000-9604.2018.06.05\">10.21147/j.issn.1000-9604.2018.06.05</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30700929/\">https://pubmed.ncbi.nlm.nih.gov/30700929</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L02BG06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Exemestane;
